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Could IL-6 inhibition prevent exercise-induced fat loss in RA? 
Antonios Stavropoulos-Kalinoglou and George D. Kitas  
New research indicates that tocilizumab limits the beneficial effects of exercise on 
abdominal fat loss. What does this mean for patients with chronic disease who are being 
treated with tocilizumab or other inhibitors of IL-6 signalling? 
 
Refers to Wedell-Neergaard A. S. et al. Exercise-induced changes in visceral adipose tissue mass are 
regulated by IL-6 signalling: a randomized controlled trial. Cell Metabolism 
https://doi.org/10.1016/j.cmet.2018.12.007 (2018) 
 
Main text 
In a new randomized controlled trial, Wedell-Neergaard and colleagues 1 investigated the 
effects of IL-6 inhibition on exercise-induced changes in visceral adipose tissue mass. They 
treated abdominally obese adults with either tocilizumab (an anti-IL-6 receptor monoclonal 
antibody) or placebo as well as either a 12-week aerobic (bicycle) exercise regimen or no 
exercise. Visceral adiposity was reduced only in the placebo group who were performing the 
exercise regimen, suggesting that IL-6 signalling is necessary for exercise-mediated 
reduction of visceral fat. This interesting finding is potentially important for the 
management of patients with rheumatoid arthritis (RA). 
The important role of IL-6 in the pathophysiology of RA is well-established2. This 
pleiotropic cytokine is produced by many cell types, including monocytes, T cells, B cells, 
fibroblasts, osteoblasts and endothelial cells. Serum and synovial fluid concentrations of IL-6 
in patients with RA are high and correlate with disease activity and joint destruction. IL-6 is 
involved in a number of pathways that can contribute to pathogenesis of RA, including: T 
cell differentiation, proliferation and apoptosis; B cell maturation and autoantibody 
production; neutrophil migration; osteoclast maturation and pannus proliferation. IL-6 is 
also the primary driver of systemic manifestations of RA, such as the acute phase response, 
anaemia, fatigue, fever and muscle weakness. This pivotal function of IL-6 has been 
confirmed in the ’clinical arena‘, as multiple controlled clinical trials and long-term 
observational studies have shown that inhibition of IL-6 reduces inflammatory disease 
activity, improves physical function and decelerates the progression of radiological joint 
damage.  
IL-6 is also involved in energy metabolism and is produced by skeletal muscle, 
especially in response to repetitive muscle contraction. Initially thought to be secreted as a 
result of muscle damage, IL-6 is now known to be released as a response to muscle glycogen 
depletion and seems to participate in glucose homeostasis and lipolysis3. In particular, IL-6 
seems to enhance visceral adipose tissue lipolysis, as indicated by the new study from 
Wedell-Neergaard et al. 1. Notably, these positive effects of IL‐6 and other myokines are 
usually associated with their transient production and short‐term action 4. The effects of 
chronically elevated IL-6, as in the case of patients with RA, on metabolism have not yet 
been investigated. 
Control of body weight and improvement of body composition are particularly 
important targets in the overall management of RA because such abnormalities are common 
in RA patients and associate with disease outcomes, including the well-established increase 
in their cardiometabolic risk5. The role of exercise in achieving these targets in the RA 
population is increasingly being recognised6. Many patients with RA present with altered body 
composition, often with reduced lean body mass in the presence of unaltered or slightly 
elevated weight, a condition termed rheumatoid cachexia. Rheumatoid cachexia is associated 
with worse RA disease outcomes, increased disability and reduced quality of life7. 
Counterintuitively, being overweight or obese is also very common in RA populations today. 
Obesity is not only a risk factor for the development of RA, but is also associated with worse 
disease outcomes and poor response to DMARDs, including some biologic agents  8 but not 
tocilizumab; this made some authors suggest that it may be a good choice for obese RA 
patients9.  In this respect, the findings of Wedell-Neergaard et al., that IL-6 inhibition may 
attenuate the beneficial effects of exercise on visceral adiposity, are important, as they argue 
against IL-6 inhibition being a good therapeutic choice in overweight RA patients. 
To date, only one study has investigated IL-6 inhibition in relation to body composition 
in RA 10. Tournadre et al. 10 showed that after 12 months of treatment with tocilizumab, 
patient weight and lean body mass were slightly increased. Interestingly, although total fat 
mass was unchanged in these patients, a change in fat distribution was reported, with truncal 
to peripheral fat ratio decreasing substantially (that is, relatively more fat was stored in the 
periphery). These results seem to indicate a beneficial effect of inhibiting IL-6 signalling. 
However, the lack of an alternative treatment control group and absence of an exercise 
intervention in this study limits our ability to compare and  interpret these findings relative 
to the findings of Wedell-Neergaard et al. 1.  Nevertheless, some potentially ’telling‘ 
differences between these studies might enlighten us.  
Wedell-Neergaard et al. 1 investigated people with obesity in a low-grade 
inflammatory state, whereas Tournadre et al. 10 investigated patients with RA exhibiting 
chronic high-grade inflammation with elevated levels of IL-6 and IL-6 receptor (IL-6R) 
expression. Even during targeted inhibition, IL-6 and IL-6R expression can remain high in 
patients with RA compared with healthy individuals, and this high expression might enable 
some IL-6-mediated effects to still occur in certain tissues. The slightly increased lean body 
mass after IL-6 inhibition in patients with RA reported by Wedell-Neergaard et al. 1 is also an 
interesting finding that might indicate that adequate levels of IL-6 for muscle regeneration 
may still be available even after inhibition in RA. IL-6 has a positive effect on the proliferative 
capacity of muscle stem cells, inducing muscle adaptation and regeneration 4. Unfortunately 
neither study reported the level of IL-6 or IL-6R expression post-treatment in blood or relevant 
tissues, e.g. muscle or fat. 
Both studies included mainly female participants, but the patients studied in 
Tournadre et al.10  were mostly of normal weight, whereas obese individuals were the focus 
of Wedell-Neergaard et al.1. This difference might indicate that further mechanisms might 
exist that involve total body adiposity adipocyte size or other factors. Moreover, the duration 
of the two studies was different, with the Tournadre et al. (9) study lasting 12 months and 
Wedell-Neergaard et al. (1) only 12 weeks. Perhaps short versus long-term IL-6 inhibition 
differentially affects mechanisms of lipolysis and energy metabolism, something that has not 
been assessed in any population.  
In conclusion, the paper by Wedell-Neergaard et al.1 contributes to our understanding 
of the mechanisms by which exercise can mediate abdominal fat loss in otherwise healthy but 
obese people. However, limited information exists regarding such mechanisms in the context 
of chronic inflammatory conditions such as RA, in which IL-6 is a major therapeutic target. 
Given the importance of adiposity and body composition in RA disease progression and 
outcome, more research is needed to understand the interaction between pharmacological 
and lifestyle interventions in this population. 
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Figure 1: Potential interactions between exercise and IL-6 inhibition in Rheumatoid Arthritis 
 
 
